E. Lundholm

The dual PPARα/γ agonist tesaglitazar blocks progression of pre‐existing atherosclerosis in APOE*3Leiden.CETP transgenic mice

J. Jukema, L. Havekes, G. Camejo, 2009, British journal of pharmacology.

Dual PPAR&agr;/&ggr; Agonist Tesaglitazar Reduces Atherosclerosis in Insulin-Resistant and Hypercholesterolemic ApoE*3Leiden Mice

J. Jukema, T. Kooistra, L. Havekes, 2006 .

The Dual PPARα/γ Agonist Tesaglitazar Reduces Atherosclerosis Development Beyond its Plasma Cholesterol-Lowering Effects in APOE*3Leiden Transgenic Mice

J. Jukema, T. Kooistra, G. Camejo, 2006 .

Dual PPARalpha/gamma agonist tesaglitazar reduces atherosclerosis in insulin-resistant and hypercholesterolemic ApoE*3Leiden mice.

J. Jukema, T. Kooistra, L. Havekes, 2006, Arteriosclerosis, thrombosis, and vascular biology.

Tesaglitazar, a PPARα/γ Agonist, Induces Interstitial Mesenchymal Cell DNA Synthesis and Fibrosarcomas in Subcutaneous Tissues in Rats

U. Andersson, H. Hellmold, G. Camejo, 2007 .

Tesaglitazar, a PPARalpha/gamma agonist, induces interstitial mesenchymal cell DNA synthesis and fibrosarcomas in subcutaneous tissues in rats.

U. Andersson, H. Hellmold, G. Camejo, 2007, Toxicological sciences : an official journal of the Society of Toxicology.